nvironment at the site is impacted by 1,2-dichloroethane (1,2-DCA) and vinyl chloride (VC) about 300,000 and 500 ?g/L in groundwater, respectively. Knowing the general persistence of 1,2-DCA in the environment, initial laboratory tests evaluated various remedial technologies: two different chemical oxidants (ISCO) and biochemical anaerobic reduction (ISCR). Of the two oxidants tested, only the activated persulfate was effective; RegenOx showed no activity whatsoever. Although the ISCR reactions required a longer treatment time, both 1,2-DCA and VC were completely removed in less than sixty days, without the accumulation of dead-end catabolites.
The use of EHC for ISCR was subsequently chosen for field-scale test, considering its minimal geochemical impact on soil and groundwater conditions. The initial field test area was ca. 50 m2 and the total volume of saturated soil treated was ca. 700 m3. A total of 6,300 kg of EHC amendment was injected through nine injection points using direct-push technology. Groundwater monitoring from four proximal observation wells showed a widespread and sustained reduction in redox (Eh -150 mV to -450 mV) and, most significantly, within ca. 9 months the groundwater concentrations of both 1,2-DCA and VC were reduced from ca. 800,000 ?g/L to in to below the regulatory treatment standards (SSTL) of 1,500 ?g/L, with two of the monitoring wells containing < 10 ?g/L 1,2-DCA.
Design of full-scale site remediation using the EHC ISCR technology is being completed. Simultaneously, continued monitoring of the field site t time on-going to verify the effective reagent life and document lack of “rebound” which is typical for many other remedial technologies. Full scale implementation will employ 600 to 700 tonnes of EHC to treat an area measuring 7,000 m2 and is planned for 2009 through 2011
A complete copy of the Report is available via PDF at
Page: 1 2 3 4 Related biology technology :1
Copyright©2009 Vocus, Inc.
All rights reserved
. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy2
. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB3
. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy4
. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals5
. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities6
. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting7
. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology8
. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period9
. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant10
. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program11
. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.